-
CFDA informs the reform of drug approval system
Time of Update: 2014-10-14
Issued by the State Food and Drug Administration on October 13, 2014 On October 9, 2014, the State Food and Drug Administration held the "Symposium on handling key suggestions of the second session of
-
New drug samples in Shanghai free trade zone will be cleared 50%
Time of Update: 2014-10-14
Recently, on the eve of the first anniversary of the establishment of Shanghai Free Trade Zone, the leaders of the State Council held a discussion with 10 Chinese and foreign entrepreneurs in the free
-
Qilu pharmaceutical ondansetron hydrochloride injection is approved to be listed in the United States
Time of Update: 2014-10-13
FDA of the United States is currently recognized as the most stringent drug review in the world, in which the quality control, hardware facilities, staffing, production specifications and other requir
-
CFDA approved sanofitasotide (docetaxel injection) for the first-line treatment of advanced gastric cancer
Time of Update: 2014-10-10
This scheme, which is composed of docetaxel combined with cisplatin and 5-fluorouracil (DCF scheme), is used to treat advanced gastric adenocarcinoma, including adenocarcinoma at the junction of stoma
-
List of enterprise varieties certified by gap from 2004 to 2014
Time of Update: 2014-10-10
List of enterprise varieties certified by gap from 2004 to 2014 Nanyang Zhangzhongjing dogwood Co., Ltd dogwood 2004 Ya'an Sanjiu traditional Chinese medicine technology industrialization Co., Ltd Hou
-
CDE drug review report in September 2014
Time of Update: 2014-10-10
Next, let's take a look at the application and acceptance of chemical medicine, traditional Chinese medicine and biological products 1、 In September, CDE undertook 659 new chemical registration applic
-
Launch of "technical service for preclinical evaluation of new drugs" project of STS program of Chinese Academy of Sciences
Time of Update: 2014-10-10
At the site of STS kick-off meeting, at the same time with the project, there are also "biotechnology drug R & D service", "medical testing service and technology development" and other projects of "d
-
Development of anti Ebola drug jk-05 by Sihuan pharmaceutical and Academy of Military Sciences
Time of Update: 2014-10-10
The new drug is one of about 15 experimental drugs against Ebola virus, which has been proved effective in cell culture and animal experiments in laboratories around the world The Ebola epidemic has k
-
CDE agrees to approve the listing of apatinib
Time of Update: 2014-10-08
Apatinib is a small molecule tyrosine kinase inhibitor independently developed by Hengrui medicine It can selectively inhibit the tyrosine kinase activity of vascular endothelial growth factor recepto
-
Application for clinical trial of bromocriptine mesylate, a new diabetes drug of Hanyu pharmaceutical, was accepted
Time of Update: 2014-10-07
According to reports, bromocriptine mesylate tablet (bromoergocin tablet) is a new type II diabetes treatment drug approved by FDA in May 2009 The new drug is the first diabetes drug to pass the risk
-
Baiyunshan No.1 Pharmaceutical Co., Ltd. invested 20 million yuan to carry out multi-dimensional evidence-based verification of Zishenyutai pill
Time of Update: 2014-10-01
Grasp the favorable factors of the new deal At the end of last year, the decision of the Central Committee of the Communist Party of China on several major issues of comprehensively deepening reform a
-
New drug varieties of Hisilicon gradually enter the market
Time of Update: 2014-09-30
Statistics show that, as of yesterday, in the third quarter report of pre happy shares (excluding the listing of new shares in September), Hisense's accumulated net inflow of large single capital rank
-
Apatinib, a heavyweight new drug of Hengrui medicine, is expected to be approved within one month
Time of Update: 2014-09-29
According to the public data, apatinib belongs to class 1 chemical medicine It is a me better drug modified on the basis of vandetanib and PTK787, which is suitable for cancer patients after the failu
-
The application for the production of flutamidazole, a new class 3.1 antibiotic of Enhua Pharmaceutical Co., Ltd. was accepted
Time of Update: 2014-09-26
According to the public information, flutromazole is a new type of local imidazole antifungal drug with broad-spectrum antibacterial activity, which was developed by urich pharmaceutical company in Sp
-
HongRi pharmaceutical industry intensively applied for three different types of new drugs
Time of Update: 2014-09-26
Both rofluorostat and L-malic acid are new drugs of class 3.1 Among them, rofluorostat is a phosphodiesterase-4 (PDE-4) inhibitor, which is a new COPD treatment drug It was developed by necomine, Swit
-
A new class of radiofibrosis drugs jointly developed by lijiexin pharmaceutical and Fujian Medical University
Time of Update: 2014-09-26
At present, radiotherapy is the main treatment method for lung cancer, nasopharyngeal cancer and other tumors In his research, Professor Zhang Lulong found a kind of low toxic small molecular compound
-
Ye Zuguang: so far, China has only produced two internationally recognized new Chinese medicines
Time of Update: 2014-09-26
Ye Zuguang believes that in the past 30 years, there are not only a large number of new Chinese medicine drugs developed and put on the market in China, but also a new drug array at the forefront of
-
Zhongyuan Xiehe will cooperate with Nobel Prize winners to build an international research and development platform for cell biotherapy
Time of Update: 2014-09-26
According to the public information, in December 2012, the company's subsidiaries and zebio signed a patent technology exclusive license agreement with British cell therapy Co., Ltd represented by Mar
-
Eighty percent of the first class new drugs in Hunan Province were developed in Liuyang
Time of Update: 2014-09-22
Four days later, Guo kaiang, member of the Standing Committee of the CPC Hunan Provincial Committee and head of the Organization Department, came to Liuyang on the 19th to conduct a special investigat
-
Suoyuan bio obtained the global authorization of phase III antitumor drug enzastaurin from Lilly
Time of Update: 2014-09-20
----Denovo US San Diego location -------------- denovo China Hangzhou location this is the first time for a Chinese pharmaceutical company to obtain a global license for clinical phase III innovative
